Barzilai Medical Center

Ashkelon, Southern District 7830604

1 studies enrolling now · 7 studies all time

What they study most

Heart Failure With Preserved Ejection Fraction (HFpEF), Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, Myelofibrosis, Obesity, Progressive Pulmonary Fibrosis, Rheumatoid Arthritis, Type 2 Diabetes Mellitus

Studies at this site

• Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis — Stopped early
• Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease — Enrolling by invitation
• A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment — Running, not enrolling
• A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes — Completed
• A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis — Completed
• A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial — Completed
• An Extension Study in Participants With Moderate to Severe Rheumatoid Arthritis — Completed